Gestonorone Acetate CAS 31981-44-9 is a high-quality commercially accessible chemical substance. It is a C17a acetate ester of gestronol (17a-hydroxy-19-norprogesterone). This molecule has been utilized as an experimental luteinizing hormone in endometrial cancer investigations, and it also inhibits testosterone decrease by the hair follicle. In addition to its progestogen effects, Gestonorone Acetate stimulates the kidneys and bladder. It has a lengthy history of use in medical research and is now being employed in various benign prostatic hyperplasia investigations.
Gestonorone acetate (developmental code name NSC-31981-44-9) is a progestin that is not used in humans. It is a C17a acetate ester of hydromadinone, an unmarketed progestin of the 19-norprogesterone and 17a-hydroxyprogesterone families. It was patented in 1958 and given medical approval in 1963.
The terms etynodiol diacetate and gestonorone acetate are synonyms, however gestonorone acetate is more commonly used. The latter name refers to gestonorone acetate as well as a popular progestin. However, etynodiol is a synthetic hormone with no progestin action. "Gestonorone Acetate" is probably not a topic you should be exploring unless you are a scientist or scholar.
Gestonorone Acetate CAS 31981-44-9 is a precursor in the production of several progestins. It is a steroidal progestin that has been demonstrated in rats to increase body weight and promote atrophy of the prostate, uterus, and seminal vesicles. It is also a reductive pathway inhibitor of Testosterone (T155000) metabolism.
It is employed in the treatment of benign prostatic hyperplasia. It is administered as a suspension or injection. It is often taken twice a week.
Gestonorone Acetate has been established in several studies to be safe and well-tolerated in patients with benign prostatic hyperplasia. Loss of appetite and moderate fever are common side effects. It has been proven to lower erythrocyte count and hemoglobin levels, however these levels return to normal if the drug is discontinued.
Endometrial cancer is also treated with the chemical. In a pilot study with FIGO stage I endometrial cancer with myometrial invasion, gestonorone caproate (17a-hydroxy-19-norpregn-4-en 3,20 dione) proved beneficial for one year. It was given in the morning at a dose of 200 mg once a week. A larger experiment is now being conducted. It is thought to lower the chance of recurrence in these women.
Hunan Yuxin Pharmaceutical Co. Ltd was established in 2002. It is a large pharmaceutical firm that specialized in steroid and hormone API and intermediates. Numerous goods like Prednisolone CAS 50-24-8 have received certifications such as GMP, DMF No., and WC (Written Confirmation), among others. It is a significant player in the international steroid business.
The company for Prednisone CAS 53-03-2 has significant synthesis and fermentation capabilities. It opened two R&D labs in Changsha. One of the two is the manufacturing site. It also works closely with the university. It has 550 people and two GMP production facilities.
We collaborate with our customers through a range of approaches, including Custom Synthesis and Contract Research. Custom fabrication for Mometasone Furoate CAS 83919-23-7 is also possible.
Yuxin Pharmaceutical Co., Ltd. develops and markets hormone APIs and intermediates such as Estrogen Corticosteroids, Methylprednisolone acetate CAS 53-63-1, Corticosteroids, or Estrogen for pharmaceutical firms worldwide.
Hunan Yuxin Pharmaceutical Co., ltd. Privacy policy Terms and Conditions
EN 
ES
PT
DE
TR
FR
